Matches in SemOpenAlex for { <https://semopenalex.org/work/W1790290811> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W1790290811 endingPage "361" @default.
- W1790290811 startingPage "361" @default.
- W1790290811 abstract "In a phase II study of axitinib for cytokine-refractory metastatic renal cell carcinoma, median overall survival (OS) was 29.9 months (95% CI, 20.3 to not estimable months).Long-term survival data were collected retrospectively from 52 patients with cytokine-refractory metastatic renal cell carcinoma who received axitinib in a completed phase II study (protocol 1), 11 of whom enrolled in a continuing access protocol (protocol 2), for the current observational study (protocol 3). In a post hoc analysis, the patients were grouped into quartiles based on cycle 1 day 1, 1- to 2-hour post-dose axitinib plasma levels to explore the impact of drug exposure on efficacy.The 5-year survival rate was 20.6% (95% CI, 10.9%-32.4%), with a median follow-up of 5.9 years. Frequent all-grade adverse events were fatigue (n = 38; 73.1%), diarrhea (n = 34; 65.4%), hypertension (n = 33; 63.5%), and nausea (n = 33; 63.5%). Quartile 3 patients (axitinib level, 45.2-56.4 ng/mL; n = 12) had the best clinical outcome: objective response rate 82%, median progression-free survival (PFS) 28.3 months, and median OS that was not reached after 5 years.Axitinib was well tolerated and provided an estimated 5-year survival rate of 20.6% for cytokine-refractory metastatic renal cell carcinoma. Exploratory analyses showed numerically higher objective response rate and longer OS and PFS in patients who achieved post–first-dose axitinib plasma concentrations within a specific range." @default.
- W1790290811 created "2016-06-24" @default.
- W1790290811 creator A5002648450 @default.
- W1790290811 creator A5013952219 @default.
- W1790290811 creator A5037386757 @default.
- W1790290811 creator A5050532099 @default.
- W1790290811 creator A5057146057 @default.
- W1790290811 creator A5061176953 @default.
- W1790290811 creator A5063149530 @default.
- W1790290811 creator A5072354631 @default.
- W1790290811 creator A5082610705 @default.
- W1790290811 creator A5083932173 @default.
- W1790290811 date "2009-09-01" @default.
- W1790290811 modified "2023-10-18" @default.
- W1790290811 title "6501 Sunitinib (SU) vs placebo for treatment of progressive, well- differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial" @default.
- W1790290811 doi "https://doi.org/10.1016/s1359-6349(09)71223-6" @default.
- W1790290811 hasPublicationYear "2009" @default.
- W1790290811 type Work @default.
- W1790290811 sameAs 1790290811 @default.
- W1790290811 citedByCount "5" @default.
- W1790290811 countsByYear W17902908112012 @default.
- W1790290811 countsByYear W17902908112018 @default.
- W1790290811 countsByYear W17902908112021 @default.
- W1790290811 crossrefType "journal-article" @default.
- W1790290811 hasAuthorship W1790290811A5002648450 @default.
- W1790290811 hasAuthorship W1790290811A5013952219 @default.
- W1790290811 hasAuthorship W1790290811A5037386757 @default.
- W1790290811 hasAuthorship W1790290811A5050532099 @default.
- W1790290811 hasAuthorship W1790290811A5057146057 @default.
- W1790290811 hasAuthorship W1790290811A5061176953 @default.
- W1790290811 hasAuthorship W1790290811A5063149530 @default.
- W1790290811 hasAuthorship W1790290811A5072354631 @default.
- W1790290811 hasAuthorship W1790290811A5082610705 @default.
- W1790290811 hasAuthorship W1790290811A5083932173 @default.
- W1790290811 hasConcept C121332964 @default.
- W1790290811 hasConcept C126322002 @default.
- W1790290811 hasConcept C126894567 @default.
- W1790290811 hasConcept C142424586 @default.
- W1790290811 hasConcept C143998085 @default.
- W1790290811 hasConcept C2776539811 @default.
- W1790290811 hasConcept C2777472916 @default.
- W1790290811 hasConcept C2779490328 @default.
- W1790290811 hasConcept C2781068499 @default.
- W1790290811 hasConcept C71924100 @default.
- W1790290811 hasConcept C87355193 @default.
- W1790290811 hasConcept C90924648 @default.
- W1790290811 hasConceptScore W1790290811C121332964 @default.
- W1790290811 hasConceptScore W1790290811C126322002 @default.
- W1790290811 hasConceptScore W1790290811C126894567 @default.
- W1790290811 hasConceptScore W1790290811C142424586 @default.
- W1790290811 hasConceptScore W1790290811C143998085 @default.
- W1790290811 hasConceptScore W1790290811C2776539811 @default.
- W1790290811 hasConceptScore W1790290811C2777472916 @default.
- W1790290811 hasConceptScore W1790290811C2779490328 @default.
- W1790290811 hasConceptScore W1790290811C2781068499 @default.
- W1790290811 hasConceptScore W1790290811C71924100 @default.
- W1790290811 hasConceptScore W1790290811C87355193 @default.
- W1790290811 hasConceptScore W1790290811C90924648 @default.
- W1790290811 hasIssue "2" @default.
- W1790290811 hasLocation W17902908111 @default.
- W1790290811 hasOpenAccess W1790290811 @default.
- W1790290811 hasPrimaryLocation W17902908111 @default.
- W1790290811 hasRelatedWork W2002301813 @default.
- W1790290811 hasRelatedWork W2041921283 @default.
- W1790290811 hasRelatedWork W2089996625 @default.
- W1790290811 hasRelatedWork W2109954950 @default.
- W1790290811 hasRelatedWork W2551353941 @default.
- W1790290811 hasRelatedWork W2562937744 @default.
- W1790290811 hasRelatedWork W2584812602 @default.
- W1790290811 hasRelatedWork W3080833635 @default.
- W1790290811 hasRelatedWork W4226147939 @default.
- W1790290811 hasRelatedWork W4380151496 @default.
- W1790290811 hasVolume "7" @default.
- W1790290811 isParatext "false" @default.
- W1790290811 isRetracted "false" @default.
- W1790290811 magId "1790290811" @default.
- W1790290811 workType "article" @default.